Department of Interventional Radiology, Ningbo First Hospital, Ningbo.
Department of Oncology. Binzhou People's Hospital, Binzhou.
Surg Laparosc Endosc Percutan Tech. 2020 Aug 5;31(1):61-65. doi: 10.1097/SLE.0000000000000848.
The purpose of this study was to assess the clinical efficacy and long-term outcomes of radioactive stent insertion in patients with malignant common biliary obstruction (MCBO).
This was a retrospective study conducted at a single-center. Consecutive patients with MCBO were treated by normal or radioactive stent insertion between January 2014 and December 2019. The baseline data, instant efficacy records, and the long-term outcome results of these 2 groups were compared.
During the experimental duration, at our center 71 patients with inoperable MCBO underwent normal (n=40) or radioactive (n=31) stent insertion. Rates of technical success of normal and radioactive stent insertions were both 100%. No patients exhibited procedure-related complications. All patients achieved improvements in their liver functions at 2 weeks after stent insertion. Stent dysfunction was recorded in 11 and 6 patients from the normal and radioactive stent groups, respectively (P=0.425). The median stent patency was 165 and 222 days with the normal and radioactive stents, respectively (P<0.001). All patients died due to tumor progression at the follow-up. Patients survived for a respective median of 182 and 242 days in the normal and radioactive stent groups (P<0.001). The complication rates were comparable between the 2 groups.
Radioactive stent insertion may provide longer patency and overall survival in those exhibiting inoperable MCBO than normal stent insertion.
本研究旨在评估放射性支架置入治疗恶性胆总管阻塞（MCBO）的临床疗效和长期预后。
这是一项单中心回顾性研究。2014 年 1 月至 2019 年 12 月，对连续就诊的 MCBO 患者行常规或放射性支架置入治疗，比较两组患者的基线资料、即刻疗效记录和长期预后结果。
在研究期间，本中心共 71 例不可切除的 MCBO 患者接受了常规（n=40）或放射性（n=31）支架置入。常规和放射性支架置入的技术成功率均为 100%。无患者发生与操作相关的并发症。所有患者在支架置入后 2 周肝功能均得到改善。常规和放射性支架组分别有 11 例和 6 例患者出现支架功能障碍（P=0.425）。常规和放射性支架的中位支架通畅时间分别为 165 天和 222 天（P<0.001）。所有患者在随访期间均因肿瘤进展而死亡。常规和放射性支架组患者的中位生存时间分别为 182 天和 242 天（P<0.001）。两组患者的并发症发生率相似。
与常规支架置入相比，放射性支架置入可为不可切除的 MCBO 患者提供更长的支架通畅时间和总生存期。
